Papers - Matsushita, Maiko

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells

Matsushita M., Kashiwazaki S., Kamiko S., Kobori M., Osada M., Kunieda H., Hirao M., Ichikawa D., Hattori Y.

Pharmaceuticals (Pharmaceuticals)  16 ( 10 )  2023.10

Research paper (scientific journal), Joint Work, Lead author, Corresponding author, Accepted

　View Summary

Several anti-cancer drugs are known to have immunomodulatory effects, including immunogenic cell death (ICD) of cancer cells. ICD is a form of apoptosis which is caused by the release of damage-associated molecular patterns (DAMPs), the uptake of cancer antigens by dendritic cells, and the activation of acquired immunity against cancer cells. ICD was originally reported in solid tumors, and there have been few reports on ICD in multiple myeloma (MM). Here, we showed that proteasome inhibitors, including carfilzomib, induce ICD in myeloma cells via an unfolded protein response pathway distinct from that in solid tumors. Additionally, we demonstrated the potential impact of ICD on the survival of patients with myeloma. ICD induced by proteasome inhibitors is expected to improve the prognosis of MM patients not only by its cytotoxic effects, but also by building strong immune memory response against MM cells in combination with other therapies, such as chimeric antigen receptor—T cell therapy.

• Access to Document (DOI)

GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c-MET tyrosine kinase

Okayama M., Fujimori K., Sato M., Samata K., Kurita K., Sugiyama H., Suto Y., Iwasaki G., Yamada T., Kiuchi F., Ichikawa D., Matsushita M., Hirao M., Kunieda H., Yamazaki K., Hattori Y.

Cancer Medicine (Cancer Medicine)  12 ( 8 ) 9749 - 9759 2023.04

Research paper (scientific journal), Joint Work, Accepted

　View Summary

Objective: Despite the development of newly developed drugs, most multiple myeloma (MM) patients with high-risk cytogenetic abnormalities such as t(4;14) or del17p relapse at anin early stage of their clinical course. We previously reported that a natural product,komaroviquinone (KQN), isolated from the perennial semi-shrub Dracocephalum komarovi, i.e., komaroviquinone (KQN) and its derivative GTN024 induced the apoptosis of MM cells by producing reactive oxygen species (ROS), but both exhibited significant hematological toxicity. Aim of this study is to clarify anti-tumor activity, safety and pharmacokinetics of GTN057, an optimization compound of KQN in vivo. Methods: ICR/SCID xenograft model of KMS11, a t(4;14) translocation-positive MM cell line, was used for in vivo study. Mice pharmacokinetics of GTN057 and the degradation products were analyzed by LC-MS/MS. Results: Herein, our in vitro experiments revealed that GTN057 is much less toxic to normal hematopoietic cells, induced the apoptosis of both MM cell lines andpatient samples, including those with high-risk cytogenetic changes. A xenograft model of a high-risk MM cell line demonstrated that GTN057 significantly delayed the tumor growth with no apparent hematological or systemic toxicities in vivo. The pathological examination of GTN057-treated tumors in vivoshowed revealed apoptosis of MM cells and anti-angiogenesis. In addition to the production of ROS, GTN057 inhibited the downstream signaling of c-MET, a receptor tyrosine kinase a receptor forand hepatocyte growth factor (HGF) receptor. Thus, GTN057 is less toxic and is able tomay be a candidate drug for treating MM patients, via multifunctional mechanisms. We have also extensively studied the pharmacologyical analysis of GTN057. The metabolites of GTN057, (e.g.,such as GTN054), may also have anti-tumorantitumor activity. Conclusion: Natural products or and their derivatives can could be good sources of antineoplastic drugs even for high-risk cancer.

• Access to Document (DOI)

PAX5-positive plasma cell leukemia presenting as lymphocytosis

Tateno S, Hirao M, Kikuchi T, Tsukada Y, Kunieda H, Osada M, Yamazaki K, Denda R, Hirose S, Matsushita M, Ichikawa D, Hattori Y.

Rinsho Ketsueki (日本血液学会)  63 ( 10 ) 1415 - 1420 2022.11

Research paper (scientific journal), Joint Work, Accepted

Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells.

Hattori Y, Futo T, Uozaki R, Ichikawa D, Yamaguchi T, Yamamoto T, Matsushita M, Hirao M.

International Journal of Hematology 115 ( 4 ) 605 - 608 2022.02

Research paper (scientific journal), Joint Work, Accepted

Characteristics of a Novel Target Antigen Against Myeloma Cells for Immunotherapy

Maiko Matsushita, Saku Saito, Shinya Yokoe, Daiju Ichikawa and Yutaka Hattori

Vaccines (MDPI)  8 ( 4 ) 579 - 591 2020.10

Research paper (scientific journal), Lead author, Corresponding author, Accepted

　View Summary

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Despite the availability of therapeutic treatments, multiple myeloma is an incurable haematological disorder. In this study, we aimed to clarify the role of CXorf48 as a therapeutic target in multiple myeloma. Based on a previously identified HLA-A*24:02-restiricted epitope from this novel cancer/testis antigen, we characterized the activities of cytotoxic T lymphocytes (CTLs) specific to this antigen against myeloma cells and evaluated the effects of demethylating agents in increasing antigen expression and enhancing the cytotoxic activity of CTLs. CXorf48 expression was examined by reverse transcription polymerase chain reaction (RT-PCR) using nine myeloma cell lines. Cell lines with low CXorf48 expression were treated by demethylating agents (DMAs), 5-azacytidine (5-aza), and 5-aza-2'-deoxycytidine (DAC) to evaluate gene expression using quantitative RT-PCR. Furthermore, CXorf48-specific CTLs were induced from peripheral blood mononuclear cells of HLA-A*24:02-positive healthy donors to evaluate antigen recognition using ELISpot and51 Cr cytotoxicity assays. CXorf48 was widely expressed in myeloma cells, and gene expression was significantly increased by DMAs. Furthermore, CXorf48-specific CTLs recognized DMA-treated myeloma cells. These findings suggest that CXorf48 is a useful target for immunotherapy, such as vaccination, in combination with demethylating agents for the treatment of patients with myeloma.

• Access to Document (DOI)

A Study on the Description of Anticancer Drug Combination Therapy in Package Insert

Shibata S, Matsushita M, Tsukamoto K, Chiba K, Ozaki K, Suzuki T

BPB Reports (The Pharmaceutical Society of Japan)  3 ( 5 ) 157 - 165 2020.10

Research paper (scientific journal), Joint Work, Accepted

Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph⁺ B cells but not bone marrow stem/progenitors

Karigane D., Kasahara H., Shiroshita K., Fujita S., Kobayashi H., Tamaki S., Yamazaki R., Yahagi K., Yatabe Y., Kondoh N., Arai T., Katagiri H., Shimizu N., Sakurai M., Kikuchi T., Kato J., Shimizu T., Hayakawa T., Yaguchi T., Matsushita M., Nakajima H., Kawakami Y., Murata M., Mori T., Sasaki T., Okamoto S., Takubo K.

Leukemia and Lymphoma (Taylor & Francis)  62 ( 3 ) 679 - 687 2020.10

Research paper (scientific journal), Joint Work, Accepted,  ISSN  10428194

　View Summary

© 2020 Informa UK Limited, trading as Taylor & Francis Group. Persistence of leukemic stem cells (LSCs) results in the recurrence of chronic myeloid leukemia (CML) after the administration of tyrosine kinase inhibitors (TKIs). Thus, the detection of minimal residual disease (MRD) with LSC potential can improve prognosis. Here, we analyzed 115 CML patients and found that CD25 was preferentially expressed on the phenotypic stem and progenitor cells (SPCs), and TKI therapy decreased the number of CD25-positive cells in the SPC fraction. To detect MRD harboring BCR-ABL1 fusion DNA, we developed a highly-sensitive method using patient-specific primers and next-generation sequencing. By using this method, we identified that in patients who achieved molecular remission, almost all residual CD25-positive SPCs were BCR-ABL1-negative. Moreover, in some patients BCR-ABL1 was detectable in peripheral B cells but not in SPCs. We conclude that CD25 marks LSCs at diagnosis but does not mark MRD following TKI treatment and that analysis of peripheral B cells can allow sensitive detection of MRD.

• Access to Document (DOI)

A phenylphthalimide derivative, TC11, induces apoptosis by degrading MCL1 in multiple myeloma cells

Ichikawa D., Nakamura M., Murota W., Osawa S., Matsushita M., Yanagawa H., Hattori Y.

Biochemical and Biophysical Research Communications (ELSEVIER)  521 ( 1 ) 252 - 258 2020.01

Research paper (scientific journal), Accepted,  ISSN  0006291X

　View Summary

© 2019 To date, the prognosis of multiple myeloma (MM) in patients harboring cytogenetic abnormalities (CA) involving t (4; 14) and deletion of chromosome 17 remains poor despite recent advances in drug development that include the use of immunomodulatory drugs (IMiDs) such as lenalidomide for MM. To address this issue, we have developed a novel phenylphthalimide derivative, TC11, that is structurally related to IMiDs. It remains unclear how TC11 induces apoptosis of MM cells with high-risk CA. Here, we show that TC11 does not induce degradation of CRBN's substrates, IKZF1/3 and CK1α, and induces apoptosis of CRBN-silenced MM; this effect was independent of the cereblon (CRBN) pathway, which is involved in the mechanism of action of IMiDs used for the treatment of MM. We also revealed that TC11, in contrast to existing IMiDs, induced degradation of MCL1 and activation of caspase-9. Furthermore, inhibition of CDK1 by CGP74514A prevented TC11-induced MCL1 degradation, caspase-9 activation, and the subsequent apoptotic cell death. We showed that ectopic MCL1 expression rescued apoptosis of MM. These observations suggest that TC11 induces apoptotic death caused by degradation of MCL1 during prolonged mitotic arrest. Therefore, our findings suggest that TC11 is a potential drug candidate for high-risk MM.

• Access to Document (DOI)

A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress.

Okayama M, Kitabatake S, Sato M, Fujimori K, Ichikawa D, Matsushita M, Suto Y, Iwasaki G, Yamada T, Kiuchi F, Hirao M, Kunieda H, Osada M, Okamoto S, Hattori Y

Biochem Biophys Res Commun (Biochemical and Biophysical Research Communications)  505 ( 3 ) 787 - 793 2018.10

Research paper (scientific journal), Joint Work, Accepted,  ISSN  0006291X

　View Summary

© 2018 Elsevier Inc. New drugs have significantly improved the survival of patients with multiple myeloma (MM), but the prognosis of MM patients with high-risk cytogenetic changes such as t(4; 14), t(14; 16) or del17p remains very poor. A natural product, komaroviquinone (KQN), was originally isolated from the perennial semi-shrub Dracocephalum komarovi and has anti-protozoal activity against Trypanosoma cruzi, the organism causing Chagas’ disease. Here we demonstrate that a novel KQN-derivative, GTN024, has an anti-MM effect both in vitro and in vivo. GTN024 induced the apoptosis of MM cell lines including those with high-risk cytogenetic changes. GTN024 produced reactive oxygen species (ROS) and increased phosphorylated eIF2α. The ROS production and subsequent endoplasmic reticulum (ER) stress are thought to play a key role in GTN024-induced apoptosis, as the apoptosis was completely abrogated by anti-oxidant treatment. In a mouse xenograft model, an intraperitoneal injection of 20 mg/kg of GTN024 significantly delayed tumor growth. Hematological toxicity and systemic toxicity as indicated by weight loss were not observed. These results suggest that the novel KQN-derivative GTN024 could become a candidate drug for treating high-risk MM.

• Access to Document (DOI)

Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

Shoyo Shibata,Maiko Matsushita,Yoshimasa Saito,Takeshi Suzuki

Therapeutic Innovation & Regulatory Science (Therapeutic Innovation and Regulatory Science)  52 ( 6 ) 718 - 723 2018.03

Research paper (scientific journal), Joint Work, Accepted,  ISSN  21684790

　View Summary

© The Author(s) 2018. Background: Despite their benefits, the rapid development of new cancer treatments has been a significant driver of increasing health care expenditures in the face of limited health care budgets. In this study, we analyzed the prescribing trends for anticancer drugs from 2010 through 2016 in Japan and sought to identify unique trends that could provide a basis for future medical economic research aiming to develop more efficacious and cost-effective cancer therapies. Methods: We used publicly available marketing data for anticancer drugs in Japan for 2010-2016. The drugs selected for this research were categorized according to the Anatomical Therapeutic Chemical Classification System. We investigated the overall anticancer drug market size, the number of anticancer drugs, the top 30 selling anticancer categories, sales and prescription volumes, and changes in sales and prescription volumes between 2010 and 2016 in the country. Results: The anticancer agent market expanded each year from 2010 to 2016, with sales exceeding 1 trillion yen in 2015. The proportion of molecular targeted drugs (antineoplastic mAbs and protein kinase inhibitors) among the top 30 selling anticancer categories has continued to increase, and both the sales and prescription volumes of these drugs exceeded those of drugs in other categories, suggesting that these treatments play a dominant role in cancer pharmacotherapy. Conclusion: The availability and increasing use of innovative but more expensive targeted therapies were major drivers of increases in pharmaceutical expenditures for cancer treatment in Japan. Therefore, the effective use of genetic testing can mitigate these rising costs.

• Access to Document (DOI)

Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy

Matsushita M., Kawaguchi M.

Journal of Oncology (Journal of Oncology)  2018 2018

ISSN  16878450

　View Summary

Recent advances in cancer immunotherapy, including immune checkpoint inhibitors or adoptive T cell therapies, have contributed to better outcomes in cancer patients. However, there are still many cancers with no cure. Therefore, combinations of several treatment strategies are being explored, and enhancing anticancer immunity will play an important role to combat the disease. There have been several reports on the immune-modulatory effects of commonly used drugs, namely, statin, metformin, and angiotensin receptor blockers (ARBs), which suggest that these drugs could enhance immunity against cancer cells. Other anticancer drugs, such as anthracyclines, thalidomides, lenalidomides, and hypomethylating drugs, could also strengthen the immune system to attack cancer cells at a relatively low dose. Hence, these drugs might contribute to better outcomes in cancer patients.

• Access to Document (DOI)

Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan

Shoyo Shibata,Maiko Matsushita,Yoshimasa Saito,Takeshi Suzuki

Therapeutic Innovation & Regulatory Science (Therapeutic Innovation and Regulatory Science)  52 ( 4 ) 442 - 448 2017.12

Research paper (scientific journal), Joint Work, Accepted,  ISSN  21684790

　View Summary

© The Author(s) 2017. Background: The increased use of generic drugs is a good indicator of the need to reduce the increasing costs of prescription drugs. Since there are more expensive drugs compared with other therapeutic areas, “oncology” is an important one for generic drugs. The primary objective of this article was to quantify the extent to which generic drugs in Japan occupy each level of the Anatomical Therapeutic Chemical (ATC) classification system. Methods: The dataset used in this study was created from publicly available information obtained from the IMS Japan Pharmaceutical Market database. Data on the total amount of sales and number of prescriptions for anti-cancer drugs between 2010 and 2016 in Japan were selected. The data were categorized according to the third level of the ATC classification system. Results: All categories of the ATC classification system had increased market shares in Japan between 2010 and 2016. The barriers to market entry were relatively low in L01F (platinum anti-neoplastics), L01C (plant-based neoplastics), L02B (cytostatic hormone antagonists), and L01D (anti-neoplastic antibiotics) but were high in L02A (cytostatic hormones), L01H (protein kinase inhibitors), and L01B (anti-metabolites). Conclusions: Generic cancer drugs could bring savings to Japanese health care systems. Therefore, their development should be directed toward niche markets, such as L02A, L01H, and L01B, and not competitive markets.

• Access to Document (DOI)

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.

Matsushita M,Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, Ichikawa D, Matsuki E, Sakurai M, Karigane D, Kasahara H, Tsukamoto N, Shimizu T, Mori T,Nakajima H, Okamoto S, Kawakami Y, Hattori Y.

Blood Cancer J. 7 ( 9 ) e601. 2017.09

Research paper (scientific journal), Accepted

Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma

Suto Y,Sato M,Fujimori K,Kitabatake S,Okayama M,Ichikawa D,Matsushita M,Yamagiwa N,Iwasaki G,Kiuchi F,Hattori Y,

Bioorganic & Medicinal Chemistry Letters 27   4558 - 4563 2017.08

Research paper (scientific journal), Joint Work, Accepted

A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest.

Aida S, Hozumi M, Ichikawa D, Iida K, Yonemura Y, Tabata N, Yamada T,Matsushita M,Sugai T, Yanagawa H, Hattori Y.

Biochem Biophys Res Commun. 493 ( 1 ) 514 - 520 2017.08

Research paper (scientific journal), Accepted

An Emprical Study of the Prescription Pattern of Drugs for Haematological Malignancies in Japan from 2010-2014.

Shibata S,Wayama Y, Tsuyuki A, Matsushita M, Chiba K, Matsuki E, Okamoto S, Suzuki T

Biol.Pharm.Bull 40 ( 6 ) 894 - 901 2017.06

Joint Work, Accepted

Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies

Matsushita MOtsuka Y, Tsutsumida N, Tanaka C, Uchiumi A, Ozawa K, Suzuki T, Ichikawa D, Aburatani H, Okamoto S, Kawakami Y, Hattori Y.

PLoS One 11 ( 1 ) e0146371 2016.01

Joint Work, Accepted

A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts.

Matsushita Maiko, Ozaki Y, Hasegawa Y, Terada F, Tabata N, Shiheido H, Yanagawa H, Oikawa T, Matsuo K, Du W, Yamada T, Hozumi M, Ichikawa D, Hattori Y.

PLoS One 10 ( 1 ) e0116135 2015.01

Research paper (scientific journal), Joint Work, Accepted

Codon 72 Polymorphism of TP53 Gene Is a Novel Prognostic Marker for Thalidomide Therapy in Multiple Myeloma.

Hattori Y, Ikeda Y, Suzuki Y, Ichikawa D, Matsushita M.

British Journal of Haematology 165 ( 5 ) 728 - 731 2014.01

Research paper (scientific journal), Joint Work, Accepted

Detection of leukemia associated antigen-specific cytotoxic T cells in a patient with Philadelphia chromosome-positive leukemia during treatment with dasatinib.

Matsushita M, Tonegawa K, Mori T, Kohashi S, Kato J, Matsuki E, Okamoto S, Hattori Y.

Leukemia Lymphoma 55 ( 3 ) 722 - 724 2013.06

Research paper (scientific journal), Joint Work, Accepted

A Myeloma Cell Line Established from a Patient Refractory to Thalidomide Therapy Revealed High-Risk Cytogenetic Abnormalities and Produced Vascular Endothelial Growth Factor.

Hattori Y, Du W, Yamada T, Ichikawa D, Matsunami S, Matsushita M.

Blood Cancer J 3   e115 2013.05

Research paper (scientific journal), Joint Work, Accepted

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI(3)kinase/AKT/Bcl-X(L) Activation and CD8(+) T Cell-mediated Tumor Eradication.

Zhong XS, Matsushita M*, Plotkin J, Riviere I, Sadelain M.

Mol Ther 18(2)   413-20 2010.02

Research paper (scientific journal), Joint Work, Accepted

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M*, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M.

Clin Cancer Res 13   5426-5435 2007.09

Research paper (scientific journal), Joint Work, Accepted

Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.

Matsushita M*, Yamazaki R, Ikeda H, Mori T, Sumimoto H, Fujita T, Okamoto S, Ikeda Y, Kawakami Y.

Br J Haematol 132(1)   56-65 2006.01

Research paper (scientific journal), Joint Work, Accepted

Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer.

Ito K, Fujita T, Akada M, Kiniwa Y, Tsukamoto M, Yamamoto A, Matsuzaki Y, Matsushita M*, Asano T, Nakashima J, Tachibana M, Hayakawa M, Ikeda H, Murai M, Kawakami Y.

Int J Cancer 108(5)   712-724 2004.02

Research paper (scientific journal), Joint Work, Accepted

Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer.

Ito K, Fujita T, Akada M, Kiniwa Y, Tsukamoto M, Yamamoto A, Matsuzaki Y, Matsushita M, Asano T, Nakashima J, Tachibana M, Hayakawa M, Ikeda H, Murai M, Kawakami Y

International Journal of Cancer 108 ( 5 ) 712-724 2004

Research paper (scientific journal), Single Work

Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.

Matsushita M*, Yamazaki R, Ikeda H, Kawakami Y.

Leuk Lymphoma 44(3)   439-44 2003.03

Research paper (scientific journal), Joint Work, Accepted

Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.

Ikeda H, Matsushita M, Waisfisz Q, Kinoshita A, Oostra AB, Nieuwint AW, De Winter JP, Hoatlin ME, Kawai Y, Sasaki MS, D'Andrea AD, Kawakami Y, Joenje H.

Cancer Research 63 ( 10 ) 2688-2694 2003

Research paper (scientific journal), Joint Work, Accepted

造血器腫瘍における腫瘍抗原と免疫療法

Matsushita Maiko, Ikeda Hideyuki, Kawakami Yutaka

現代医療 31 ( 5 ) 1155-1160 1999.05

Research paper (scientific journal), Joint Work

造血器腫瘍における腫瘍抗原と免疫療法

Matsushita Maiko, Ikeda Hideyuki, Kawakami Yutaka

現代医療 31 ( 5 ) 1155-1160 1999.05

Research paper (scientific journal), Joint Work

PRAME protein expressed in leukemia cells as a target molecule for immunotherapy.

池田英之，松下麻衣子，河上裕

Rinsho Ketsueki 40 ( 6 ) 484-486 1999

Research paper (scientific journal), Joint Work

造血器腫瘍におけるPRAME

Ikeda Hideyuki, Matsushita Maiko, Kawakami Yutaka

血液・腫瘍科 39 ( 1 ) 46-50 1999

Research paper (scientific journal), Joint Work

1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1).

Muto A, Kizaki M, Yamato K, Kawai Y, Kamata-Matsushita M, Ueno H, Ohguchi M, Nishihara T, Koeffler HP, Ikeda Y

Blood 93 ( 7 ) 2225-2233 1999

Research paper (scientific journal), Joint Work, Accepted

新しくクローニングされた癌特異抗原―PRAME

Ikeda Hideyuki, Matsushita Maiko

臨床検査 42 ( 7 ) 811-813 1998.07

Research paper (scientific journal), Joint Work